Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ibrahim Aldoss

Showing results (31-40 of 233) with videos related to

Pageof 24
Sort By:
Blood and Lymphatic Cancer : Targets and Therapy|September 13, 2022
FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell TransplantationAmanda Blackmon, Ibrahim Aldoss, Brian J Ball
American Journal of Hematology|December 1, 2018
Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for useMatthew Mei, Ibrahim Aldoss, Guido Marcucci, et al.
Acta Haematologica|December 4, 2013
The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemiaIbrahim Aldoss, Lingyun Ji, Mintallah Haider, et al.
Leukemia & Lymphoma|August 26, 2022
Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysisIdoroenyi Amanam, Dat Ngo, Vinod Pullarkat, et al.
Journal of Intensive Care Medicine|November 22, 2023
Important Considerations in the Intensive Care Management of Acute LeukemiasHoda Pourhassan, Waasil Kareem, Vaibhav Agrawal, et al.
Future Oncology (London, England)|November 14, 2025
Ponatinib in the treatment of acute lymphoblastic leukemiaTamer Othman, Dat Ngo, Jose Tinajero, et al.
Familial Cancer|June 18, 2011
The identification and management of hereditary diffuse gastric cancer in a large Jordanian familyHenry T Lynch, Ibrahim Aldoss, Jane F Lynch
Blood|May 12, 2025
How I Treat: Revisiting the myth of second remission in acute lymphoblastic leukemia in the era of immunotherapyIbrahim Aldoss, Mary C Clark, Stephen J Forman
Expert Opinion on Biological Therapy|December 23, 2025
Current status and future potential of CD123-based targeted therapies for acute leukemiaShukaib Arslan, Ahmed Aribi, Anthony Stein, et al.
Current Oncology Reports|November 30, 2022
Asparaginase: How to Better Manage Toxicities in AdultsHoda Pourhassan, Dan Douer, Vinod Pullarkat, et al.
Pageof 24

Showing results (31-40 of 233) with videos related to

Sort By:
Pageof 24
Blood and Lymphatic Cancer : Targets and Therapy|September 13, 2022
FLT3 Inhibitors as Maintenance Therapy after Allogeneic Stem-Cell TransplantationAmanda Blackmon, Ibrahim Aldoss, Brian J Ball
American Journal of Hematology|December 1, 2018
Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for useMatthew Mei, Ibrahim Aldoss, Guido Marcucci, et al.
Acta Haematologica|December 4, 2013
The combination of fludarabine, cytarabine and etoposide is an active and well-tolerated regimen in relapsed/refractory acute myeloid leukemiaIbrahim Aldoss, Lingyun Ji, Mintallah Haider, et al.
Leukemia & Lymphoma|August 26, 2022
Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysisIdoroenyi Amanam, Dat Ngo, Vinod Pullarkat, et al.
Journal of Intensive Care Medicine|November 22, 2023
Important Considerations in the Intensive Care Management of Acute LeukemiasHoda Pourhassan, Waasil Kareem, Vaibhav Agrawal, et al.
Future Oncology (London, England)|November 14, 2025
Ponatinib in the treatment of acute lymphoblastic leukemiaTamer Othman, Dat Ngo, Jose Tinajero, et al.
Familial Cancer|June 18, 2011
The identification and management of hereditary diffuse gastric cancer in a large Jordanian familyHenry T Lynch, Ibrahim Aldoss, Jane F Lynch
Blood|May 12, 2025
How I Treat: Revisiting the myth of second remission in acute lymphoblastic leukemia in the era of immunotherapyIbrahim Aldoss, Mary C Clark, Stephen J Forman
Expert Opinion on Biological Therapy|December 23, 2025
Current status and future potential of CD123-based targeted therapies for acute leukemiaShukaib Arslan, Ahmed Aribi, Anthony Stein, et al.
Current Oncology Reports|November 30, 2022
Asparaginase: How to Better Manage Toxicities in AdultsHoda Pourhassan, Dan Douer, Vinod Pullarkat, et al.
Pageof 24